Cargando…
HER2-positive gastric cancer
Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor outcomes of several types of cancer, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs, such as trastuzumab, which prolong overall survival and progression-free survival i...
Autor principal: | Boku, Narikazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889288/ https://www.ncbi.nlm.nih.gov/pubmed/23563986 http://dx.doi.org/10.1007/s10120-013-0252-z |
Ejemplares similares
-
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
por: Sawaki, Akira, et al.
Publicado: (2011) -
Trastuzumab deruxtecan for the treatment of patients with
HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021) -
Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018) -
Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
por: Kahraman, Seda, et al.
Publicado: (2021) -
HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
por: Pous, Anna, et al.
Publicado: (2023)